Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583811 | PMC |
| http://dx.doi.org/10.1002/ctm2.70101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Stratification Using DIPSS and Splenomegaly in Myelofibrosis Treated with Pre-Transplant JAK inhibitors.
Transplant Cell Ther
September 2025
Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.
The Dynamic International Prognostic Scoring System for primary myelofibrosis (DIPSS) has been reported to predict transplant outcomes in myelofibrosis (MF) patients. Recently, the pre-transplant use of JAK inhibitors has become common in clinical practice, but it is unclear whether DIPSS is also useful for predicting transplant outcomes for these patients. In this study, we compared the prognostic impact of DIPSS between MF patients with and without pre-transplant Ruxolitinib therapy.
View Article and Find Full Text PDFTriple A Plus (AAA) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients.
Am J Hematol
September 2025
CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, AOU Careggi, Florence, Italy.
Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple-A (AAA) prognostic score. The latter enlists age and absolute neutrophil (ANC) and lymphocyte (ALC) counts as risk variables. In the current study, a Mayo Clinic discovery cohort of 658 patients with ET was used to identify AAA-independent risk variables.
View Article and Find Full Text PDFCardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes.
Blood Vessel Thromb Hemost
August 2025
Division of Oncology, Massachusetts General Hospital, Boston, MA.
Cardiovascular risk factors (CVRFs) are important modifiers of thrombosis in patients with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). We performed a retrospective cohort analysis evaluating CVRFs in 1005 patients with myeloproliferative neoplasms (MPNs) from the Dana-Farber Cancer Institute Hematologic Malignancies Data Repository from 2014 to 2023. We also included a non-MPN group of 1543 age- and sex-matched controls with no known diagnoses of hematologic malignancies to evaluate whether CVRFs differentially affected outcomes.
View Article and Find Full Text PDFA Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia.
Am J Hematol
July 2025
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
This study aimed to distinguish between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) using routine blood tests, with a focus on white blood cell (WBC) and platelet (PLT) levels. We evaluated the predicted probability of a pre-PMF diagnosis based on the interaction between WBC and PLT levels using data from a logistic regression model involving 891 patients with ET and 180 patients with pre-PMF. Patients were divided into four groups based on whether their WBC and PLT values were below or above the respective thresholds of 8.
View Article and Find Full Text PDFPrognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study.
J Inflamm Res
July 2025
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Introduction: Myelofibrosis (MF) is a rare myeloproliferative neoplasm (MPN) characterized by significant mortality and limited predictive biomarkers. The red cell distribution width to albumin ratio (RAR), a novel biomarker indicative of inflammation, has emerged as a strong prognostic indicator in the general population but remains unexplored in MF.
Methods: We retrospectively enrolled 504 consecutive MF patients from 7 hematological centers over a 10-year period.